(Finance) – Valnevaa French company specializing in vaccines, announced that theEuropean Medicines Agency (EMA) performed a technical validation of the marketing authorization application (MAA) for the single-dose vaccine candidate against chikungunya of Valneva (VLA1553) and ascertained that all the essential regulatory elements required for scientific evaluation were included in the application.
One was obtained last month accelerated assessment by the Committee for Medicinal Products for Human Use (CHMP) on the basis of “great interest for public health and therapeutic innovation” of the vaccine candidate.
“We welcome the acceptance of the MAA review by the EMA and will work closely with them to bring VLA1553 to the market – he commented Juan Carlos Jaramillo, Chief Medical Officer by Valneva – The Chikungunya virus, or CHIKV, has already spread to over 110 countries and the risk of spread of chikungunya in Europe is relatively high due to the possibility of infected travellers. There are currently no specific vaccines or treatments available for this debilitating disease, which therefore constitutes an unmet medical need. Following the approval of VLA1553 in the United States, we will continue to work diligently to bring VLA1553 to other territories as soon as possible.